Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $62.8333.

A number of research firms recently weighed in on SUPN. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $21,908,000. Assenagon Asset Management S.A. purchased a new position in Supernus Pharmaceuticals during the 1st quarter worth $27,428,000. Woodline Partners LP boosted its holdings in Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after acquiring an additional 490,835 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Supernus Pharmaceuticals by 2,847.0% in the 1st quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock worth $19,498,000 after acquiring an additional 364,413 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after acquiring an additional 338,584 shares in the last quarter.

Supernus Pharmaceuticals Trading Down 2.4%

Supernus Pharmaceuticals stock opened at $46.57 on Thursday. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -91.31, a price-to-earnings-growth ratio of 1.02 and a beta of 0.54. The firm’s fifty day moving average price is $46.42 and its two-hundred day moving average price is $49.17. Supernus Pharmaceuticals has a 1-year low of $32.83 and a 1-year high of $59.68.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.